Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL604888 | 0.84 | HRH3 (0.73) | HRH3HRH4 | |
| SCHEMBL1985057 | 0.83 | HRH3 (0.71) | HRH3HRH4 | |
| SCHEMBL605303 | 0.82 | HRH3 (1.00) | HRH3HRH4 | |
| SCHEMBL1998160 | 0.82 | HRH3 (0.70) | HRH3HRH4 | |
| SCHEMBL14574663 | 0.81 | HRH3 (0.65) | HRH3HRH4 | |
| SCHEMBL1991948 | 0.81 | HRH3 (0.68) | HRH3HRH4 | |
| SCHEMBL607428 | 0.80 | HRH3 (0.80) | HRH3HRH4 | |
| SCHEMBL20472913 | 0.80 | HRH3 (0.67) | HRH3HRH4 | |
| SCHEMBL20472917 | 0.80 | HRH3 (0.67) | HRH3HRH4 | |
| SCHEMBL1996943 | 0.80 | HRH3 (0.67) | HRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516420-B1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | MEDICIS PHARMACEUTICAL CORP (US) | 2018-08-22 | — | — | EP | claimed |
| US-8901146-B2 | Aminoalkylpyrimidine derivatives as histamine H4 receptor antagonists | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2014-12-02 | — | — | US | claimed |
| US-20130018031-A1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-01-17 | — | — | US | claimed |
| EP-2516420-A1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | Palau Pharma, S.A. (ES) | 2012-10-31 | — | — | EP | claimed |
| WO-2011076878-A1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | WO | claimed |
| EP-2516420-B1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | MEDICIS PHARMACEUTICAL CORP (US) | 2018-08-22 | — | — | EP | disclosed |
| US-8901146-B2 | Aminoalkylpyrimidine derivatives as histamine H4 receptor antagonists | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130018031-A1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-01-17 | — | — | US | disclosed |
| WO-2011076878-A1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018031-A1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | HRH4, HRH2, HRH3 | HRH3 3/4885HRH4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.